Sequence: e4k4-x-PLGLAG-r9-x-c
| Experiment Id | EXP001671 |
|---|---|
| Paper | Tumor-Targeting and Microenvironment-Responsive Smart Nanoparticles for Combination Therapy of Antia |
| Peptide | dtACPP |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | Dose: 50 µg DNA + 8 µg DOX per mouse (tail vein), repeated dosing (days 12,15,18 post-implantation) |
| Rna Concentration | 50 µg DNA/mouse (+ 8 µg DOX) |
| Mixing Ratio | DGL:DNA w/w 6:1; DOX intercalated |
| Formulation Format | PEGylated DGL nanoparticles (peptide-PEG-DGL/DNA complexes) |
| Formulation Components | Dendrigraft poly-L-lysine (DGL G3) + MAL-PEG-NHS (PEG 3500) + dtACPP peptide; complexes with plasmid shVEGF (± DOX intercalated) |
| Size Nm | 145.00 |
| Zeta Mv | 2.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Intracranial U-87 MG glioma-bearing nude mice |
| Administration Route | Intravenous (tail vein) |
| Output Type | antitumor efficacy |
| Output Value | Median survival ~58.5 days; strongest tumor apoptosis (TUNEL/Annexin imaging) |
| Output Units | |
| Output Notes | In vivo apoptosis imaging and TUNEL; improved survival vs free DOX or gene-only groups |
| Toxicity Notes | Gentlest loss in body weight among treated groups; described as little side effects |
| Curation Notes |